To clarify if the expression level of CDCA7 had an impact on patients’ clinical features, we subsequently collected data on clinical features, including 1p/19q codeletion status, IDH mutation status, age, gender, WHO grade, and histological diagnosis of the patients, and found that with the increase in the CDCA7 expression level, the clinicopathological changes and survival status of patients with glioma showed a trend of deterioration in both CGGA and TCGA databases (Figure 3A,B). The gene discussed is CDCA7; the disease is central nervous system cancer.